RCUS - Arcus Biosciences, Inc.

NYSE - NYSE Delayed Price. Currency in USD
6.44
-0.36 (-5.29%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close6.80
Open6.75
Bid6.37 x 800
Ask7.75 x 800
Day's Range6.36 - 6.91
52 Week Range6.30 - 16.06
Volume121,755
Avg. Volume191,476
Market Cap286.805M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire

    Arcus Biosciences to Present at Upcoming Investor Conferences

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that the Company will partici

  • Business Wire

    Arcus Biosciences Announces Second Quarter 2019 Financial Results and Recent Corporate Updates

    - Progressing our lead program, AB928, a potential best-in-class dual A2a/A2b receptor antagonist, into multiple dose-expansion cohorts in 2H19, including metastatic castration res

  • Business Wire

    Arcus Biosciences Appoints Global Immuno-Oncology Commercial Leader, Eric Hoefer as Chief Commercial Officer

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Eric Hoefer has joined the Company as Chief Commercial Officer. Mr. Hoefer will oversee all aspects of the Company’s global commercial strategy and operations as the Company works to ensure that it most efficiently leverages the clinical and market development opportunities for its therapeutic candidates.

  • Business Wire

    Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that the Company will host a conference call and live webcast on Tuesday, June 25, 2019, at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time to provide a mid-year update on its clinical and preclinical programs. Following the live webcast, a replay will be available on the Company’s website for approximately 30 days. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies. Arcus has several programs targeting important oncology/immuno-oncology pathways, including a dual adenosine receptor antagonist, AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody, AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates.

  • Business Wire

    Arcus Biosciences to Present Preliminary Data from the Ongoing Phase 1 Dose-Escalation Trials of AB928 in Combination with Chemotherapy or AB122 at the 2019 ASCO Annual Meeting

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the Company will be presenting preliminary data from the ongoing Phase 1 dose-escalation trials of AB928, a potential best-in-class dual A2a/A2b receptor antagonist, in a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31-June 4, 2019. The activation of these receptors by adenosine interferes with the activity of key populations of immune cells and inhibits an optimal anti-tumor immune response.

  • Business Wire

    Arcus Biosciences to Present at the Jefferies 2019 Global Healthcare Conference

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 at 4 pm ET at the Grand Hyatt, in New York, NY. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates.

  • Business Wire

    Arcus Biosciences Announces First Quarter 2019 Financial Results and Recent Corporate Updates

    - Selected 150 mg for the dose expansion trial for AB928, the Company’s dual A2a/A2b receptor antagonist, in combination with AB122, the Company’s anti-PD-1 antibody

  • Business Wire

    Arcus Biosciences Appoints William Grossman, M.D., Ph.D., Chief Medical Officer

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that William Grossman, M.D., Ph.D. has joined the Company as Chief Medical Officer. Dr. Grossman will oversee all aspects of the Company’s global clinical development strategy and operations. “We are pleased to have Dr. Grossman join Arcus during this seminal period in the advancement and expansion of our clinical development programs,” said Terry Rosen, Ph.D., Chief Executive Officer of Arcus.

  • Business Wire

    Arcus Biosciences and Strata Oncology Announce Clinical Development Collaboration for Anti-PD-1 Antibody AB122

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, and Strata Oncology, Inc. (“Strata”), a precision oncology company, today announced that the companies have entered into a clinical development collaboration utilizing Strata’s precision drug development platform and proprietary biomarkers to evaluate AB122, Arcus’s clinical-stage anti-PD-1 antibody, in a basket trial including tumor types that are generally not responsive to anti-PD-1 therapy. As part of this partnership, Arcus will gain access to Strata’s drug development platform, featuring leading capabilities to design and conduct transformative precision therapy studies.

  • Business Wire

    Arcus Biosciences Appoints Rekha Hemrajani as Chief Operating and Financial Officer

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the appointment of Rekha Hemrajani as Chief Operating and Financial Officer. Ms. Hemrajani will be responsible for several key areas, including finance, investor relations, corporate communications, business and corporate development, strategic planning and human resources. “We are thrilled to welcome Rekha as a key member of our senior leadership team, as we enter an exciting period in Arcus’s development with multiple Phase 1 readouts for AB928, our dual A2a/A2b receptor antagonist, AB154, our anti-TIGIT antibody, and AB680, our small-molecule CD73 inhibitor,” said Terry Rosen, Ph.D., Chief Executive Officer of Arcus.

  • Business Wire

    Arcus Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Updates

    - Ended 2018 with four molecules in clinical development, including AB928, the Company’s dual A2aR/A2bR receptor antagonist, which is being evaluated in several dose-escalation tri

  • Business Wire

    Arcus Biosciences Announces Upcoming Presentations at the 2019 American Association for Cancer Research Annual Meeting

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced seven presentations at the 2019 American Association for Cancer Research Annual Meeting being held March 29-April 3, 2019 in Atlanta, Georgia.

  • Business Wire

    Arcus Biosciences Announces Participation at Upcoming Investor Conference

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 8th Annual Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019 at 11:30 am ET at the Lotte New York Palace, in New York, NY. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates.

  • Business Wire

    Arcus Biosciences Announces Transition of Chief Financial and Operating Officer

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Jennifer Jarrett will step down as the Company’s Chief Financial and Operating Officer, effective January 11, 2019, to pursue an opportunity at a privately-held transportation and technology company. Ms. Jarrett will remain actively engaged with the Company and has been appointed to Arcus’s Board of Directors commencing January 12, 2019. Ms. Jarrett and the Company have also entered into a consulting agreement that will ensure a seamless transition.

  • GlobeNewswire

    Consolidated Research: 2018 Summary Expectations for ProQR Therapeutics N.V, Biomerica, VEREIT, Apergy, Zendesk, and Arcus Biosciences — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 16, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire

    Arcus Biosciences Presents Initial Data from the Phase 1 Dose-Escalation Study of AB122, its anti-PD-1 antibody, at the SITC 2018 Annual Meeting

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced preliminary data from its ongoing Phase 1 dose-escalation study of AB122. The data are being presented today during a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C. “Preclinical data previously demonstrated that AB122 has biological, pharmacokinetic and pharmacodynamic properties similar to those of the approved anti-PD-1 antibodies and the dose-escalation data presented today represent an important step in confirming these results in patients,” said Joyson Karakunnel, MD, MSc, FACP, Vice President of Clinical Development at Arcus.

  • Business Wire

    Arcus Biosciences Announces Third Quarter 2018 Financial Results and Recent Corporate Updates

    - Three dose-escalation trials evaluating AB928, the Company’s dual adenosine receptor antagonist, in combination with other agents are now enrolling patients; Initial data from th

  • Business Wire

    Arcus Biosciences Announces Participation at Three Investor Conferences in November

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that members of the managemen

  • Business Wire

    Arcus Biosciences Appoints Kristen M. Hege, M.D., to its Board of Directors

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the appointment of Kristen M. Hege, M.D., to its Board of Directors. Dr. Hege brings more than 20 years of oncology clinical leadership experience to Arcus’s board. “We are thrilled to welcome Dr. Hege to our Board of Directors,” said Terry Rosen, Ph.D., Chief Executive Officer at Arcus.

  • Business Wire

    Arcus Biosciences to Present Final Results from the Phase 1 Study of AB928 in Healthy Volunteers at ESMO 2018 Congress

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that it will present final results from the Phase 1 study of AB928, its dual adenosine receptor antagonist, in healthy volunteers during a poster display session at the European Society of Medical Oncology (ESMO) 2018 Congress, being held October 19-23, 2018, in Munich, Germany. The safety data to be presented will demonstrate that in this study, there was no evidence of the physiological effects of blocking adenosine that have been observed clinically with earlier adenosine receptor antagonists. Physiological effects associated with the earlier adenosine receptor antagonists that were initially designed for CNS indications may potentially limit their optimal dosing in the oncology setting.

  • Business Wire

    Arcus Biosciences Announces Nine Abstracts Accepted for Presentation at the SITC 2018 Annual Meeting

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that nine abstracts have been accepted for poster presentation at the Society for Immunotherapy of Cancer Annual Meeting, which is being held from November 7-11, 2018 in Washington, D.C.

  • Business Wire

    Arcus Biosciences Announces Participation at Leerink Partners Roundtable Series: Rare Disease & Oncology

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced Terry Rosen, Ph.D., Chief Executive Officer, and Jennifer Jarrett, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Oncology on Wednesday, October 3, 2018, at 10:30 ...